Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MNCs Bank On China Generics Market

This article was originally published in PharmAsia News

Executive Summary

Many multinational companies have been planning to tap the huge potential generic drug market in China. Recently, Novartis subsidiary Sandoz China acquired Grunenthal's factory for $35 million to boost Sandoz's generics production for the China and Asia markets. Bayer has also been stepping up efforts to expand its over-the-counter drug strategy in China. Generics represent an important business for MNCs, which enjoy a good market base and prices much higher than similar domestic products. However, analysts note that the trend may be influenced by many factors, such as the government's policies on pricing and health insurance, consumers' preference for mid- to low-end generic drugs and pharma companies' managerial ability to address rapid changes in the local market conditions. (Click here for more)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066667

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel